Marta Milà‐Alomà

Predicting onset of symptomatic Alzheimerʼs disease with plasma p-tau217 clocks

A head‐to‐head comparison of plasma biomarkers to detect Alzheimer's disease in a memory clinic

Timing of Changes in Alzheimer's Disease Plasma Biomarkers as Assessed by Amyloid and Tau <scp>PET</scp> Clocks

The mediating role of neuroimaging-derived biological brain age in the association between risk factors for dementia and cognitive decline in middle-aged and older individuals without cognitive impairment: a cohort study

Plasma phosphorylated tau‐217 exhibits sex‐specific prognostication of cognitive decline and brain atrophy in cognitively unimpaired adults

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease

Plasma and CSF biomarkers in a memory clinic: Head‐to‐head comparison of phosphorylated tau immunoassays

Reactive astrogliosis is associated with higher cerebral glucose consumption in the early Alzheimer’s continuum

Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum

P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease

CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET: A Cross-sectional Study

Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected

Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's <i>continuum</i>